Novacyt Company Profile

10:44 EST 10th December 2018 | BioPortfolio

Novacyt, floated in 2012 on the Paris NYSE-Alternext exchange, is active in discovering, developing and marketing advanced and innovative solutions for liquid-based-cytology dedicated to cancer with a successful approval for cervical cancer screening and the opportunity to deploy its expertise in the field of molecular diagnostics. Within less than 5 years of focused R&D, Novacyt which was granted an innovation award by the French agency OSEO has been able to commercialise a flexible and fully automated and secure cytology instrument: the high-performance NovaPrep® Processor System. Novacyt has established a presence in France and internationally via a network of ca. 20 distributors. For more information please refer to the website:

News Articles [13 Associated News Articles listed on BioPortfolio]

Novacyt secures €4.0m funding through unsecured debt facility to support M&A strategy

PARIS & CAMBERLE, England–(BUSINESS WIRE)–Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce th...

Omega's infectious disease business to be acquired by Novacyt division

A deal has been reached by Novacyt's Lab21 protein diagnostics division to pay up to $2.9 million for Omega Diagnostics Group -More- 

Novacyt unit enters exclusive assay supply deal with US laboratory

Primerdesign, the molecular testing unit of Novacyt, has entered an exclusive supply agreement with US laboratory Genesis Dia -More- 

Novacyt partners with Applied Microarrays

The US partnership aims to facilitate the design and optimisation of customised microarray assays

Novacyt completes substantial q16 molecular diagnostics order

Expands clinical diagnostic reach in fast growing Chinese market

CLIA Waiver Study Guidelines Simplified By US FDA In Latest Revisions

FDA took the unusual step of issuing a second round of draft guidance documents in its effort to refine requirements...   

US FDA Redrafts Glucose Meter Guidances With Small Updates

The agency finalized two parallel guidance documents in 2016 relating to hospital point-of-care and patient over-the-counter use of blood glucose...   

$4.66M debt facility secured by French diagnostics firm

An unsecured debt facility worth approximately $4.6 million was secured by French diagnostics company Novacyt from an undiscl -More- 

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


Novacyt, floated in 2012 on the Paris NYSE-Alternext exchange, is active in discovering, developing and marketing advanced and innovative solutions for liquid-based-cytology dedic...

Novacyt and Leica Biosystems

More Information about "Novacyt" on BioPortfolio

We have published hundreds of Novacyt news stories on BioPortfolio along with dozens of Novacyt Clinical Trials and PubMed Articles about Novacyt for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novacyt Companies in our database. You can also find out about relevant Novacyt Drugs and Medications on this site too.

Quick Search


Relevant Topics

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record